Skip to main content
. 2018 Aug 8;4(9):e380. doi: 10.1097/TXD.0000000000000819

FIGURE 1.

FIGURE 1

Treatment groups and dosing regimens are shown from the full analysis set, including the parent study (A3921030; NCT00483756) and the LTE study (A3921050; NCT00658359). CsA 125 to 400 ng/mL and 100 to 300 ng/mL represent the target 12-hour trough whole blood levels. All patients received concomitant mycophenolic acid product and corticosteroid taper through month 72.